HD-OPM Archive
Hashtags

#atorvastatin

34 posts

Statins do not slow coronary calcium; severe-calcification odds hit 4.48 after 10+ years

Dec 02, 2025 · Gokhan Can ♥ 17 · 💬 41 Statins

Evidence review concluding statins reduce events and soft plaque but do not slow Agatston CAC progression, and that long-term cohorts show calcification accelerating without plateau, interpreted as plaque repair into stable scar. Trials: St. Francis (CAC unchanged, events down 33%), SALTIRE (progression 26% vs 18%) and BELLES (similar progression, ~11-14%).

Japan-ACS: pitavastatin and atorvastatin both regressed coronary plaque by about 17-18%

Sep 13, 2025 · Louis Nervegna ♥ 19 · 💬 23 ↩ 21 Plaque, CAC & CT angiography

Summary of the Japan-ACS trial, in which over 300 acute coronary syndrome patients were randomized to pitavastatin or atorvastatin and imaged with IVUS. Both statins produced similar, substantial regression of non-culprit plaque volume as LDL fell into the 80s mg/dL, which is one reason statins remain standard care after ACS.

Case report: 10 mg atorvastatin cleared most of a severe LAD blockage over 4 years

Oct 06, 2025 · Louis Nervegna ♥ 29 · 💬 14 Statins

Responding to influencers who say plaque cannot be reversed with statins, Louis cites a case report in which a patient taking low-dose atorvastatin went from a severe to a mild LAD narrowing, documented on CT angiography. It is a single case, but illustrates that statin-associated plaque regression can occur.

Only lipophilic statins like atorvastatin enter the brain; PCSK9 drugs and ezetimibe don't

Oct 18, 2025 · Louis Nervegna ♥ 25 · 💬 10 Brain health & dementia

Louis explains the blood-brain barrier and cholesterol: the brain makes its own cholesterol separately from blood, so non-statin LDL drugs and hydrophilic statins like rosuvastatin have little brain effect. Lipophilic statins do enter the brain, with promising observational data against Alzheimer's, and a 20,000-person atorvastatin trial is under way. Two prior trials showed statins do not worsen existing Alzheimer's, and midlife high LDL is a leading modifiable dementia risk (2024 Lancet Commission, about 7% of US cases per Louis).

Atorvastatin may 'disarm' Lp(a) by blocking oxidation, a theory for HORIZON's failure

Nov 10, 2026 · Louis Nervegna ♥ 9 · 💬 12 ↩ 1 Lp(a)

Louis proposes that Lp(a)HORIZON failed because aggressive statin treatment (78% on high-intensity statins) may have already neutralized oxidized phospholipids carried by Lp(a). A shared abstract (Sherratt et al., Eur Heart J) found atorvastatin's active metabolite scavenges free radicals and inhibits oxidation of Lp(a) and small dense LDL better than other statins. This is a lab-based hypothesis.

Atorvastatin improved kidney function dose-dependently across 6 RCTs with 30,621 patients

Oct 13, 2024 · Louis Nervegna ♥ 11 · 💬 9 ↩ 1 Statins

Louis cites a JAHA post hoc analysis of six double-blind outcome trials in patients at risk of or with cardiovascular disease. Atorvastatin improved kidney function over time in a dose-dependent way, and improvement in kidney function was associated with lower cardiovascular risk. The authors suggest kidney function could serve as a surrogate end point.

PREVENTABLE: 20,000-person trial of atorvastatin 40 mg to prevent dementia over age 75

Jun 23, 2025 · Louis Nervegna ♥ 16 · 💬 5 Statins

Louis describes the ongoing PREVENTABLE trial, which randomizes about 20,000 community-dwelling adults aged 75+ to atorvastatin 40 mg or placebo to test whether statins prevent dementia. Atorvastatin was chosen because it is lipophilic and crosses the blood-brain barrier; the trial began in 2020 and is still recruiting.

STAREE: atorvastatin cut major CV events 30% in adults 70+ with no rise in dementia

Nov 01, 2026 · Louis Nervegna ♥ 5 · 💬 5 Statins

A quoted summary of the STAREE trial in NEJM: 9,971 adults aged 70 or older without cardiovascular disease, diabetes or dementia were randomized to atorvastatin 40 mg or placebo for a median 5.9 years. Atorvastatin cut major cardiovascular events 30% and MI and revascularization 43% each, with no significant increase in dementia or all-cause mortality and equal serious adverse events.

Atorvastatin is generally preferred over rosuvastatin in chronic kidney disease

Dec 08, 2025 · Louis Nervegna ♥ 4 Statins

Louis shares an MRCP UK explainer on statins in CKD: atorvastatin needs no renal dose adjustment (under 2% renal excretion), while rosuvastatin is 30% renally excreted, needs dose reduction at low eGFR and can cause reversible proteinuria at high doses. KDIGO advises a statin with or without ezetimibe in CKD stages 3-5 not on dialysis.

Amyloid-beta drives excess astrocyte cholesterol and impairs brain waste clearance in mice

Nov 03, 2026 · Louis Nervegna ♥ 2 Brain health & dementia

A Nature Neuroscience mouse study found amyloid-beta raises calcium activity in astrocytes, boosting cholesterol production and removing AQP4 water channels, which impairs the glymphatic waste-clearing system. Calming astrocytes, blocking cholesterol synthesis or giving atorvastatin restored clearance and memory in mice. Human trials are needed, but the mechanism may partly explain observational links between statin use and lower dementia risk.